# Commission Regulation (EU) 2018/782 of 29 May 2018 establishing the methodological principles for the risk assessment and risk management recommendations referred to in Regulation (EC) No 470/2009 (Text with EEA relevance), Division II.7.2

Extent: E+W+S+N.I.

For those injectable substances for which depletion of injection site residues when compared to the muscle MRL would result in extended (prohibitive) withdrawal periods, an Injection Site Residue Reference Value (‘ISRRV’) shall also be established by the appropriate authority. The ISRRV shall be set at a level that ensures that, at the likely withdrawal period, a standard food basket including 300g of injection site muscle would contain residues below the ADI.

---
Source: https://www.legislation.gov.uk/eur/2018/782/annex/II/division/II/division/II.7/division/II.7.2 (the official version)
Page: https://openlegislation.uk/eu-regulation-2018-782/annex-II/division-II/division-II.7/division-II.7.2
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.